Amgen's earnings transcript highlights significant clinical progress in their avacopan trials, particularly the ADVOCATE Phase III trial in ANCA-associated vasculitis.  Management expressed confidence in achieving positive results, leading to potential NDA submissions in the first half of 2020.  The planned cadence of data releases from multiple trials (ANCA, C3G, and HS) suggests a strong short-term outlook for the stock.
[2]
